Business Wire

Novakid Maintains Growth in 2022, Launches 40-Minute Learning Sessions

22.2.2023 18:00:00 EET | Business Wire | Press release

Share

Novakid, a leading online English as a Second Language (ESL) platform and evolving EdTech company that is reinventing learning for children, maintained customer growth with approximately 70,000 new students across 50+ countries subscribing during 2022.

Importantly, Novakid achieved double-digit YoY revenue growth, with the share of long-term subscriptions (6 and 12 months) steadily increasing. Globally, over 20% of new subscription sales are attributed to referrals from current customers and NPS is trending at above 60% (best in class), evident in the improved customer retention figures. Novakid maintained high scores for customer satisfaction - an average of 96%, depending on the region - based on internal measurement methods conducted on a regular basis.

Over 10 million lessons have been delivered since 2017, of which nearly 4.5 million lessons (4,453,732) were completed in 2022.

Novakid continued to strengthen its positions in global markets. Europe still accounts for the majority of the company’s client portfolio (55%) with the MENA region accounting for 25% of the client base and the Asia-Pacific region increasing to 20% of the total number of customers.

2023 plans

The 25-minute one-on-one English lesson format will be upgraded to a 40-minute educational journey for young students. These extended sessions are at no additional cost to clients and include three elements: a fun, context-setting pre-lesson activity, the one-on-one lesson with a teacher and gamified self-practice ‘homework’ after the lesson. Since August 2022, Novakid has noted that the average time students spend on self-practice activities beyond structured, one-to-one lessons has tripled.

New product developments that are being considered for the platform are aimed at increasing the engagement with educational content to increase motivation to learn and support learning outcomes. The team is constantly researching and testing various options, including experiments with other subjects that could be added to the product line.

Recent research has indicated that increased time spent on homework and mini games has a positive impact on the retention rate. Additionally, the monthly retention rate of users who have watched comic-based videos is 149% higher than those who have not. Ultimately, more interaction with games, videos and additional content results in higher retention rates. This insight will drive curriculum and product development going forward.

Our focus in the upcoming year will lie on further improving the value of our product for our customers. We will do this by continuing to invest in better UX for customers, and in high-quality content for our teachers helping them to be even better at teaching. We will continue expanding our offering beyond the one-to-one tutoring format. Specifically, we are planning to add self-learning activities and start introducing 1-many learning & practice products. We are grateful for the trust that our families put in us to teach their children. The results of our young English learners remain the biggest achievement for Novakid,” said Max Azarov, CEO of Novakid.

For more information about Novakid, please visit https://www.novakidschool.com/corp/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dominique Harmse, +447932928310
dominique.harmse@novakidschool.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 15:00:00 EEST | Press release

Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye